Induction of general anaesthesia

Indication for Etomidate

Population group: Suitable for both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

For this indication, competent medicine agencies globally authorize below treatments:

0.3 mg/kg

Route of admnistration


Defined daily dose

4 mg per kg of body weight

Dosage regimen

4 mg per kg of body weight once every day

Detailed description

A dose of 0.3 mg/kg bodyweight given intravenously at induction of anaesthesia, gives sleep lasting from 4 to 5 minutes.

In children under 15 years the dosage may need to be increased: a supplementary dose of up to 30% of the normal dose for adults is sometimes necessary to obtain the same depth and duration of sleep as obtained in adults.

Dosage should be adjusted to the individual patient response and to clinical effects.

Since etomidate has no analgesic action, appropriate analgesics should be used in procedures involving painful stimuli.

Hypnosis can be prolonged by additional injections of etomidate.

Do not exceed a total dose of 60 mg.

Active ingredient

Etomidate is an imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization.

Read more about Etomidate

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner